Peptide Cycling — When to Cycle, When to Run Continuously

One of the most common questions in any peptide community is "do I need to cycle this?" The answer depends entirely on the compound, its mechanism of action, and what the cycling is intended to achieve. Some compounds are almost always cycled. Others are designed for continuous use. Applying the wrong approach to a given compound can either waste time (unnecessary off periods) or reduce effectiveness (missing a needed break).

This guide breaks down the reasoning behind cycling, which compound classes benefit from it, which are typically run without interruption, and how to design and track a cycling protocol effectively.

What Is Cycling?

Cycling refers to planned periods of use ("on") alternating with periods of discontinuation ("off"). The practice originates from the anabolic steroid community, where cycling is fundamental to managing receptor sensitivity, hormonal recovery, and organ stress. In the peptide world, cycling is more nuanced — some compounds share the receptor sensitivity concerns that make cycling valuable, while others have no such mechanism and are designed for indefinite use.

The terminology is straightforward:

• On period: The duration of active compound use. May be measured in days (e.g., 5 days on) or weeks (e.g., 8 weeks on).
• Off period: The break between active cycles. Intended to allow receptor resensitisation, physiological recovery, or both.
• Cycle length: The total duration of one complete on + off rotation.
• Loading phase: Some compounds use a higher-frequency or higher-dose initial period before transitioning to a maintenance protocol. This is distinct from cycling — loading establishes a baseline, while cycling alternates between use and rest.

Cycling is distinct from titration (gradually increasing dose) and from course-based use (running a compound for a set duration to address a specific condition, then stopping). A course of BPC-157 for an injury is not cycling — it is goal-driven use with a defined endpoint. Cycling implies a repeating on/off pattern.

Why Cycle?

The reasons for cycling vary by compound class, but they generally fall into four categories:

• Receptor desensitisation (downregulation): The most pharmacologically grounded reason. Chronic stimulation of certain receptor types causes the cell to reduce receptor density or responsiveness — a protective mechanism against overstimulation. The result is diminishing returns from the same dose. A break allows receptor populations to recover. This mechanism is well-documented for growth hormone secretagogue receptors and melanocortin receptors.
• Physiological strain management: Some compounds — particularly oral anabolic compounds — place measurable stress on the liver and lipid profile during use. Cycling limits the duration of that exposure and provides recovery periods. This is not about receptor sensitivity; it is about organ recovery.
• Maintaining sensitivity: Even where full receptor downregulation has not occurred, some users report that periodic breaks maintain subjective responsiveness to a compound. This is more anecdotal than mechanistic for many peptide classes, but it is a widely followed practice.
• Cost optimisation: Peptides are not inexpensive. For compounds where continuous use provides diminishing returns (either through desensitisation or plateau effects), cycling can deliver comparable outcomes at lower total compound usage.

Compounds That Commonly Benefit from Cycling

The following compounds are most frequently associated with cycling protocols in community use and practitioner guidance. The rationale varies — receptor sensitivity for some, safety for others.

GH Secretagogues — The Desensitisation Question

The growth hormone secretagogue receptor (GHS-R1a) is the best-documented example of receptor desensitisation relevant to peptide users. GHRP-6 demonstrates the most pronounced desensitisation — studies have shown reduced GH pulse amplitude after several weeks of continuous daily use. Ipamorelin appears to have a milder desensitisation profile, which is one reason it became the preferred GH secretagogue for many users.

The two most common cycling approaches for GH peptides are:

• 5 on / 2 off (daily): Five days of dosing followed by two rest days each week — typically weekdays on, weekends off. This is the simpler pattern and is widely used for ipamorelin, GHRP-2, and CJC-1295 (no DAC). The theory is that two rest days per week provide enough receptor recovery to maintain sensitivity without a prolonged break.
• 8-12 weeks on / 4 weeks off: A longer cycle with a more substantial break. More commonly used with MK-677 and hexarelin, where the desensitisation concerns are more pronounced or where other physiological parameters (insulin sensitivity for MK-677, cortisol for hexarelin) benefit from periodic normalisation.

CJC-1295 with DAC is an exception. Its extended half-life (~8 days) means it provides continuous GHRH-like stimulation regardless of dosing pattern. Many users run it at lower injection frequencies (1-2x per week) without a traditional cycling protocol, relying on the lower peak stimulation and longer action to produce a more physiological GH elevation pattern.

Melanocortin Agonists

Melanotan II operates on the melanocortin receptor system (MC1R for tanning, MC3R/MC4R for appetite and sexual function). The typical protocol involves a loading phase — daily dosing for 2-3 weeks to build pigmentation — followed by maintenance dosing at a much lower frequency (once every 1-2 weeks) to sustain the effect. This is not cycling in the traditional sense, but the principle is similar: sustained high-frequency dosing leads to diminishing returns, while intermittent dosing maintains receptor responsiveness.

Compounds Typically Run Continuously

Not every compound benefits from cycling. Several commonly used peptides and hormones are designed for or most effective with continuous administration.

GLP-1 Receptor Agonists

Semaglutide, tirzepatide, and retatrutide are not typically cycled. The clinical trial data and prescribing frameworks for these compounds are based on continuous use. The GLP-1 receptor does not appear to desensitise in the same way that GHS receptors do — appetite suppression and glycaemic control are generally maintained with ongoing administration. Discontinuation is commonly followed by a return of appetite and, in many cases, reversal of weight loss gains. These compounds are designed as long-term interventions, not time-limited cycles.

TRT (Testosterone Replacement)

Testosterone replacement therapy is, by definition, continuous. The goal is to maintain stable physiological testosterone levels in individuals whose endogenous production is insufficient. Cycling TRT — periodic discontinuation — would reintroduce the symptoms that prompted replacement in the first place. This is distinct from performance-enhancement "blast and cruise" protocols, where supraphysiological doses are periodically used and then returned to a replacement baseline. TRT itself is not cycled.

Healing Peptides (BPC-157, TB-500)

BPC-157 and TB-500 are typically run as defined courses rather than cycled. A course of 4-12 weeks for injury recovery, gut healing, or tissue repair is the standard approach. The mechanism of action — upregulation of growth factor pathways, angiogenesis promotion, anti-inflammatory signalling — does not involve the same receptor desensitisation dynamics that affect GH secretagogues. Once the therapeutic goal is met (injury healed, symptoms resolved), the compound is discontinued. If a new injury or condition arises later, a new course is started. This is goal-driven use, not cycling.

GHK-Cu

GHK-Cu is commonly used continuously for skin quality and anti-aging applications, or in defined courses for wound healing. The copper tripeptide operates through gene expression modulation and collagen synthesis pathways that do not exhibit the acute receptor desensitisation seen with GH secretagogues. Some users alternate between periods of active use and rest for cost reasons, but the pharmacological rationale for mandatory cycling is not as established as it is for GHRP compounds.

Designing a Cycle

For compounds where cycling is appropriate, a systematic approach produces better outcomes than arbitrary on/off periods. The following framework covers the key decision points.

Reading Your Body — Signs of Desensitisation

Receptor desensitisation is a gradual process, not a sudden event. It typically presents as a slow erosion of the compound's effects despite consistent dosing and confirmed product quality. Recognising the pattern early allows for a proactive break rather than weeks of diminished returns.

For GH secretagogues, desensitisation may manifest as:

• Sleep quality improvements that were present in weeks 1-4 gradually diminishing
• Reduced subjective recovery benefit from training
• IGF-1 levels that were elevated at week 4 returning toward baseline despite continued dosing
• A plateau in body composition changes that were previously progressing

For melanocortin agonists, desensitisation may present as:

• Reduced tanning response from the same dose
• Diminished appetite-suppressive effects
• Reduced libido effects compared to initial use

The key distinction is gradual onset. A sudden loss of effect — from one day to the next — is more likely a product quality issue (degradation, contamination) or a dosing error than receptor desensitisation. Desensitisation develops over weeks, not overnight. Tracking subjective markers daily makes this trend visible in the data before it becomes obvious in felt experience. For more on recognising whether a compound is still working, see how to know if your peptides are working.